BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
149.95 EUR
+1.7 (+1.15%)
We assign a fundamental rating of 5 out of 10 to IDP. IDP was compared to 81 industry peers in the Biotechnology industry. IDP has an excellent financial health rating, but there are some minor concerns on its profitability. IDP is cheap, but on the other hand it scores bad on growth. These ratings would make IDP suitable for value investing!
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
In the past year IDP had a positive cash flow from operations.
IDP had positive earnings in each of the past 5 years.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.51%, IDP is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
IDP's Return On Equity of 8.84% is fine compared to the rest of the industry. IDP outperforms 77.78% of its industry peers.
IDP's Return On Invested Capital of 9.70% is amongst the best of the industry. IDP outperforms 85.19% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IDP is in line with the industry average of 11.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
With an excellent Profit Margin value of 15.98%, IDP belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
IDP's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 28.50%, IDP belongs to the best of the industry, outperforming 87.65% of the companies in the same industry.
IDP's Operating Margin has declined in the last couple of years.
IDP has a better Gross Margin (75.24%) than 65.43% of its industry peers.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for IDP has been increased compared to 1 year ago.
The number of shares outstanding for IDP has been reduced compared to 5 years ago.
The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
IDP has an Altman-Z score of 3.31. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
IDP's Altman-Z score of 3.31 is fine compared to the rest of the industry. IDP outperforms 70.37% of its industry peers.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.78, IDP is in the better half of the industry, outperforming 79.01% of the companies in the same industry.
IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.35, IDP perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.31 |
ROIC/WACC1.18
WACC8.23%
2.3 Liquidity
A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
IDP has a Current ratio of 2.72. This is comparable to the rest of the industry: IDP outperforms 55.56% of its industry peers.
IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
IDP has a Quick ratio of 2.04. This is comparable to the rest of the industry: IDP outperforms 46.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.56% on average over the next years.
IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.54, the valuation of IDP can be described as very reasonable.
Based on the Price/Earnings ratio, IDP is valued cheaply inside the industry as 92.59% of the companies are valued more expensively.
IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.77.
IDP is valuated reasonably with a Price/Forward Earnings ratio of 11.41.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 97.53% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.35. IDP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.54 | ||
| Fwd PE | 11.41 |
4.2 Price Multiples
88.89% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 93.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.44 | ||
| EV/EBITDA | 7.77 |
4.3 Compensation for Growth
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (12/30/2025, 7:00:00 PM)
149.95
+1.7 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap22.00B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target155.43 (3.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)0.32%
PT rev (3m)6.04%
EPS NQ rev (1m)-1%
EPS NQ rev (3m)-54.88%
EPS NY rev (1m)-1.85%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.59%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.54 | ||
| Fwd PE | 11.41 | ||
| P/S | 2.57 | ||
| P/FCF | 11.44 | ||
| P/OCF | 10.55 | ||
| P/B | 1.42 | ||
| P/tB | 10.85 | ||
| EV/EBITDA | 7.77 |
EPS(TTM)14.23
EY9.49%
EPS(NY)13.14
Fwd EY8.76%
FCF(TTM)13.11
FCFY8.74%
OCF(TTM)14.22
OCFY9.48%
SpS58.32
BVpS105.49
TBVpS13.82
PEG (NY)N/A
PEG (5Y)N/A
Graham Number183.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.31 |
F-Score5
WACC8.23%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.